KR900002769A - 장시간 작용하는 나트륨 디클로페낙의 제제 - Google Patents

장시간 작용하는 나트륨 디클로페낙의 제제 Download PDF

Info

Publication number
KR900002769A
KR900002769A KR1019890006268A KR890006268A KR900002769A KR 900002769 A KR900002769 A KR 900002769A KR 1019890006268 A KR1019890006268 A KR 1019890006268A KR 890006268 A KR890006268 A KR 890006268A KR 900002769 A KR900002769 A KR 900002769A
Authority
KR
South Korea
Prior art keywords
sodium diclofenac
sodium
weight
formulation
diclofenac
Prior art date
Application number
KR1019890006268A
Other languages
English (en)
Other versions
KR950003610B1 (ko
Inventor
미노루 오까다
시유이찌 가사이
아끼라 이와사
Original Assignee
다이도 나오가따
에스에스 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이도 나오가따, 에스에스 세이야꾸 가부시끼 가이샤 filed Critical 다이도 나오가따
Publication of KR900002769A publication Critical patent/KR900002769A/ko
Application granted granted Critical
Publication of KR950003610B1 publication Critical patent/KR950003610B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

장시간 작용하는 나트륨 디클로페낙의 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 하기 시험예 1의 용해 시험에서 얻은 결과를 보여주는 도면으로서,
시간에 대한 나트륨 디클로페낙의 용해 속도 변화를 나타내는 것이다.
제2도는 하기 시험예 2에서 얻은 결과를 나타내는 도면으로서, 시간에 대한
나트륨 디클로페낙의 용해 속도 변화를 나타내는 것이다.
제3도는 하기 시험예 3의 용해 시험에서 얻은 결과를 나타내는 도면으로서,
시간에 대한 혈장에서의 디클로페낙 농도 변화를 나타내는 것이다.
제4도는 시험예 4에서 얻은 결과를 나타내는 제3도와 같은 도면이다.

Claims (15)

  1. 나트륨 디클로페낙 및 유기산으로 구성되는 약학적 조성물 위에 서방성 피막
    을 코팅 함으로써 제조되는 서방성 나트륨 디클로페낙 성분으로 구성되는 장
    시간 작용하는 나트륨 디클로페낙의 제제.
  2. 제1항에 있어서, 나트륨 디클로페낙 100중량부당 유기산 2~50중량부로 구성
    되는 장시간 작용하는 나트륨 디클로페낙의 제제.
  3. 제1항에 있어서, 상기 서방성 피막이 pH 5.5~7의 범위의 산성수준에서 수용
    성인 장용성 중합체로 구성되는 장시간 작용하는 나트륨 디클로페낙의 제제.
  4. 제1항에 있어서, 상기 서방성 피막이 약 pH 7의 산성수준에서 수용성인 장용
    성 중합체로 구성되는 장시간 작용하는 나트륨 디클로페낙의 제제.
  5. 제1항에 있어서, 상기 서방성 피막이 수불용성 중합체로 구성되는 장시간 작
    용하는 나트륨 디클로페낙의 제제.
  6. 제1항에 있어서, 상기 서방성 피막이 에틸 셀룰로오즈 1중량부, 폴리비닐 피
    롤리돈 0.2~0.5중량부 및 탈크 0.01~1.5중량부로 구성되는 장시간 작용하는
    나트륨 디클로페낙의 제제.
  7. 제1항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  8. 제2항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  9. 제3항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  10. 제4항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  11. 제5항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  12. 제6항에 있어서, 약학적 조성물에서 상기 서방성 피막의 양이 상기 약학적
    조성물의 1~80중량%인 장시간 작용하는 나트륨 디클로페낙의 제제.
  13. (Ⅰ) 서방성 나트륨 디클로페낙 성분 및 (Ⅱ) 제제에서 총 나트륨 디클로페
    낙의 양에 대하여 나트륨 디클로페낙을 10~50중량%의 양으로 속방성 나트륨
    디클로페낙 성분이 구성되는 장시간 작용하는 나트륨 디클로페낙의 제제.
  14. 제13항에 있어서, 서방성 나트륨 디클로페낙 성분 및 속방성 나트륨 디클로
    페낙 성분이 혼합되는 장시간 작용하는 나트륨 디클로페낙의 제제.
  15. 제13항에 있어서, 서방성 나트륨 디클로페낙 성분 및 속방성 나트륨 디클로
    페낙 성분이 각각의 층을 형성하는 장시간 작용하는 나트륨 디클로페낙의 제
    제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890006268A 1988-08-16 1989-05-10 지속성 디클로페낙나트륨 제제 KR950003610B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP203498/1988 1988-08-16
JP63-203498 1988-08-16
JP20349888 1988-08-16

Publications (2)

Publication Number Publication Date
KR900002769A true KR900002769A (ko) 1990-03-23
KR950003610B1 KR950003610B1 (ko) 1995-04-17

Family

ID=16475153

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006268A KR950003610B1 (ko) 1988-08-16 1989-05-10 지속성 디클로페낙나트륨 제제

Country Status (13)

Country Link
US (1) US4968505A (ko)
JP (1) JPH07116028B2 (ko)
KR (1) KR950003610B1 (ko)
BE (1) BE1002710A5 (ko)
CA (1) CA1319616C (ko)
CH (1) CH678813A5 (ko)
DE (1) DE3915150C2 (ko)
FR (1) FR2635460B1 (ko)
GB (1) GB2221842B (ko)
HK (1) HK48194A (ko)
IT (1) IT1231517B (ko)
NL (1) NL194882C (ko)
SE (1) SE509029C2 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
US5079001A (en) * 1989-11-03 1992-01-07 Ciba-Geigy Corporation Liquid oral formulation of diclofenac
US5015481A (en) * 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US5518737A (en) * 1991-10-16 1996-05-21 Orion-Yhtyma Oy Peroral drug delivery system
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
DE4403943A1 (de) * 1994-02-08 1995-08-10 Hexal Pharma Gmbh Orale Azrneimittelzubereitung mit Diclofenac-Natrium
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
ATE321529T1 (de) * 1996-09-30 2006-04-15 Alza Corp Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
EP1690531A3 (en) * 1996-09-30 2010-01-20 Alza Corporation Dosage form and method for administering drug
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
ES2129356B1 (es) * 1997-03-26 2000-01-16 Pierre Fabre Iberica S A Forma farmaceutica de liberacion prolongada y procedimiento para su o btencion.
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
JP4260370B2 (ja) * 1998-08-10 2009-04-30 旭化成ファーマ株式会社 塩酸ファスジルの経口徐放性製剤
BR0113070A (pt) * 2000-08-10 2003-07-08 Unihart Corp Composições farmacêuticas contendo carbonato de lìtio
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
CA2591247A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
US10195154B2 (en) 2011-06-10 2019-02-05 Nipro Corporation Method for producing orodispersible tablets
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
WO2017084680A1 (en) * 2015-11-17 2017-05-26 Rontis Hellas S.A. Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
CN114306260B (zh) * 2021-12-29 2023-10-24 濮阳市汇元药业有限公司 一种新型双氯芬酸钠片及其制备方法
DE202022100544U1 (de) 2022-01-31 2022-02-16 Ranjitsing Babasing Bayas Neue orale Streifen- oder Dünnfilmform von Diclofenac-Natrium

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
CH655507B (ko) * 1983-01-12 1986-04-30
DE3328401A1 (de) * 1983-08-05 1985-02-21 Merckle GmbH, 7902 Blaubeuren Injizierbare loesung zur behandlung von entzuendungen
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
CH664085A5 (de) * 1985-02-08 1988-02-15 Ciba Geigy Ag Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung.
JPS61280426A (ja) * 1985-06-04 1986-12-11 Ikeda Mohandou:Kk 消炎鎮痛用貼付剤
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
CH675537A5 (ko) * 1988-03-25 1990-10-15 Ciba Geigy Ag

Also Published As

Publication number Publication date
BE1002710A5 (fr) 1991-05-14
GB2221842A (en) 1990-02-21
US4968505A (en) 1990-11-06
JPH02237918A (ja) 1990-09-20
NL194882C (nl) 2003-06-04
KR950003610B1 (ko) 1995-04-17
IT8948030A0 (it) 1989-06-01
HK48194A (en) 1994-05-27
GB8910271D0 (en) 1989-06-21
SE509029C2 (sv) 1998-11-30
SE8901593D0 (sv) 1989-05-03
NL8901200A (nl) 1990-03-16
FR2635460B1 (fr) 1994-09-16
DE3915150A1 (de) 1990-03-01
NL194882B (nl) 2003-02-03
JPH07116028B2 (ja) 1995-12-13
CA1319616C (en) 1993-06-29
DE3915150C2 (de) 1997-04-17
CH678813A5 (ko) 1991-11-15
SE8901593L (sv) 1990-12-06
FR2635460A1 (fr) 1990-02-23
IT1231517B (it) 1991-12-07
GB2221842B (en) 1991-10-16

Similar Documents

Publication Publication Date Title
KR900002769A (ko) 장시간 작용하는 나트륨 디클로페낙의 제제
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
KR870000069A (ko) 안정한 고체 제형의 제조 방법
DK1024795T3 (da) Formuleringer med reguleret frigivelse
KR900017572A (ko) 필름 피복 정제
KR880001288A (ko) 경구투여 형태의 서방성 약제학적 조성물
KR870002832A (ko) 제약 조성물
ATE84706T1 (de) Spheroiden.
KR930003905A (ko) 약학적 결합 제제
NO20001042D0 (no) Oftalmiske preparater med forsinket frigivelse inneholdende vannoppløselige medikamenter
ATE107857T1 (de) Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
KR860006984A (ko) 서방성 제제의 제조방법
KR880001289A (ko) 서방성 제제 및 그의 제조방법
BR0013720A (pt) Formulação em pelota de liberação controlada
KR960021060A (ko) 경구 투여용 약제학적 조성물
KR900013943A (ko) 장기작용성 제제용 약제-방출 조절 피복물질
KR920003971A (ko) 점안액 조성물
IE882898L (en) Solubility modulated drug delivery device
KR900011451A (ko) 새로운 의약품 제제
DE69616072D1 (de) Stabile feste formulierung eines enalaprilsalzes und verfahren zu deren herstellung
KR920016097A (ko) 서방성 프라노프로펜 제제
DK1009380T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer
ITTO930167A0 (it) Nuovi derivati dell'acido glutammico ed acido asparico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la memo ria e l'apprendimento.
JPS57167919A (en) Preventing agent for intraperitoneal adhesion
NO20004816L (no) Ny farmasøytisk formulering

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020410

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee